Pasithea announces enrollment of cohort 2 in Phase 1/1b trial of PAS-004

Pasithea Therapeutics (KTTA) announced that the external Safety Review Committee recommended that the Company’s Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PAS-004, in adult participants with neurofibromatosis type 1 should proceed to Cohort 2, 8mg tablet, without modification. This recommendation was based on the review of the safety data from three patients from Cohort 1 and the absence of any dose limiting toxicitie